Interleukin-15 enhances immune reconstitution after allogeneic bone marrow transplantation

被引:101
作者
Alpdogan, O [1 ]
Eng, JM [1 ]
Muriglan, SJ [1 ]
Willis, LM [1 ]
Hubbard, VM [1 ]
Tjoe, KH [1 ]
Terwey, T [1 ]
Kochman, A [1 ]
van den Brink, MRM [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA
关键词
D O I
10.1182/blood-2003-09-3344
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Interleukin-15 (IL-15) is a gamma-common cytokine that plays an important role in the development, survival, and proliferation of natural killer (NK), NK T and CD8(+) T-cells. We administered IL-15 to recipients of an allogeneic bone marrow transplantation (allo BMT) to determine its effects on immune reconstitution. Posttransplantation IL-15 administration significantly increased donor-derived CD8(+) T (mostly CD122(+)CD44(+)CD8(+) T-cells), NK, and NK T-cells at day +28 in young and old recipients of allo BMT This was associated with enhanced T-cell and NK-cell function. IL-15 stimulated homeostatic proliferation of donor CD8(+) T-cells in recipients of carboxyfluorescein diacetate succinimidyl ester-labeled donor T-cell infusions. Posttransplantation IL-15 administration also resulted in a decrease in apoptotic CD8(+) T-cells, an increase in Bcl-2-expressing CD8(+) T-cells, and an increase in the fraction of Ki67(+) proliferative NK and CD8(+) T-cells in recipients of allo BMT. IL-15 did not exacerbate graft-versus-host disease (GVHD) in recipients of T-cell-depleted BMT but could aggravate GVHD in some cases in recipients of a T-cell-repleted BMT. Finally, we found that IL-15 administration could enhance graft-versus-leukemia activity. In conclusion, IL-15 can be administered safety to recipients of a T-cell-depleted allo BMT to enhance CD8(+) T, NK, and NK T-cell reconstitution. (C) 2005 by The American Society of Hematology.
引用
收藏
页码:865 / 873
页数:9
相关论文
共 59 条
[1]  
AbdulHai A, 1996, EXP HEMATOL, V24, P1416
[2]   Administration of interleukin-7 after allogeneic bone marrow transplantation improves immune reconstitution without aggravating graft-versus-host disease [J].
Alpdogan, O ;
Schmaltz, C ;
Muriglan, SJ ;
Kappel, BJ ;
Perales, MA ;
Rotolo, JA ;
Halm, JA ;
Rich, BE ;
van den Brink, MRM .
BLOOD, 2001, 98 (07) :2256-2265
[3]   IL-7 enhances peripheral T cell reconstitution after allogeneic hematopoietic stem cell transplantation [J].
Alpdogan, Ö ;
Muriglan, SJ ;
Eng, JM ;
Willis, LM ;
Greenberg, AS ;
Kappel, B ;
van den Brink, MRM .
JOURNAL OF CLINICAL INVESTIGATION, 2003, 112 (07) :1095-1107
[4]   IL-15 induces antigen-independent expansion and differentiation of human naive CD8+ T cells in vitro [J].
Alves, NL ;
Hooibrink, B ;
Arosa, FA ;
van Lier, RAW .
BLOOD, 2003, 102 (07) :2541-2546
[5]  
ANDERSON DM, 1995, J BIOL CHEM, V270, P29862
[6]   Interleukin 15 is required for proliferative renewal of virus-specific memory CD8 T cells [J].
Becker, TC ;
Wherry, EJ ;
Boone, D ;
Murali-Krishna, K ;
Antia, R ;
Ma, A ;
Ahmed, R .
JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 195 (12) :1541-1548
[7]   IL-15 promotes the survival of naive and memory phenotype CD8+ T cells [J].
Berard, M ;
Brandt, K ;
Paus, SB ;
Tough, DF .
JOURNAL OF IMMUNOLOGY, 2003, 170 (10) :5018-5026
[8]  
Blazar BR, 1997, J IMMUNOL, V159, P3460
[9]  
Bolotin E, 1996, BLOOD, V88, P1887
[10]   INTERLEUKIN (IL)-15 IS A NOVEL CYTOKINE THAT ACTIVATES HUMAN NATURAL-KILLER-CELLS VIA COMPONENTS OF THE IL-2 RECEPTOR [J].
CARSON, WE ;
GIRI, JG ;
LINDEMANN, MJ ;
LINETT, ML ;
AHDIEH, M ;
PAXTON, R ;
ANDERSON, D ;
EISENMANN, J ;
GRABSTEIN, K ;
CALIGIURI, MA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 180 (04) :1395-1403